Buy Wegovy UK

Looking to buy Wegovy in the UK from a trusted supplier? We offer secure ordering, discreet packaging, and dependable UK delivery for customers seeking a smooth and professional shopping experience. Order online with confidence and enjoy reliable service from checkout to delivery.

What Is Wegovy?

Wegovy is a weight loss injection that can be an effective aid to support a weight loss journey – when used alongside a healthy balanced diet and increased physical activity exercise. The weight loss drug contains the active ingredient semaglutide.

Launched in the United Kingdom in 2023, Wegovy was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) for obesity management.

Wegovy is a prescription only medication for adults living with obesity. This means with a body mass index (BMI) over 30. It can also be used by people with a BMI over 27 with medical history of weight-related conditions (such as high blood pressure or type 2 diabetes).

How Wegovy Works

Wegovy works by mimicking a naturally occurring hormone called glucagon-like peptide-1 (GLP-1), which plays a role in regulating appetite.

GLP-1 acts on areas of the brain involved in hunger and satiety, helping to reduce appetite and helping the patient feel fuller for longer. Wegovy also slows the emptying of your stomach, which can help you feel satisfied for longer after eating.

By reducing hunger and increasing feelings of fullness, Wegovy supports appetite regulation, which may help patients maintain healthier eating patterns as part of a clinically supervised obesity management plan.

How to Take Wegovy

The dose is increased every 4 weeks over a titration period of up to 20 weeks. Patients start with a 0.25 mg once-weekly dose for the first 4 weeks, with the dose gradually increased to reach a maintenance dose.

For most patients, the standard maintenance dose is 2.4 mg once weekly from week 17 onwards. In selected cases, dose escalation may continue to higher maintenance dose of 7.2 mg under medical supervision.

This gradual increase is important because it helps minimise the risk of side effects. If side effects do occur, they are most commonly experienced during the dose-escalation phase and often improve over time.

Wegovy can be taken at any time of day and can be used with or without meals. It is injected subcutaneously into the abdomen, thigh, or upper arm.

Injection sites should be rotated to avoid repeatedly using the same area. For more guidance, read our Wegovy dosage guide.

Using the Wegovy Pen

Step 1: Wash your hands.

Step 2: Remove the pen cap and check the label, dose of Wegovy, expiry date, and that the solution is clear and colourless.

Step 3: Attach a new needle and remove the inner needle cap, keeping the outer cap for later.

Step 4: Perform a flow check, turn knob until you see double dots: and press, this will release a little bit of the solution to ensure flow is ready.

Step 5: Choose and wipe the injection site with a swab and let dry (abdomen, thigh, or upper arm), rotating sites each week and avoiding 5 cm around the belly button.

Step 5a: If using 7.2 mg dose, there will be 3 doses of 2.4 mg. Leave at least 5 cm between injection sites to reduce local irritation.

Step 6: Turn the dose selector until your prescribed dose lines up with the dose pointer.

Step 7: Insert the needle and press and hold the dose button until the counter shows 0, then keep holding for 6 seconds before removing.

Step 8: Add the needle cap and safely remove the needle. Dispose of the needle immediately in a sharps bin.

Step 9: Replace the pen cap and store as directed.

 

Is Wegovy Effective for Weight Loss?

Clinical trials have shown that Wegovy treatment resulted in a statistically significant reduction in body weight compared with placebo.

In phase 3 studies using the standard 2.4 mg maintenance dose, adults treated with Wegovy achieved an average of ~17% weight loss after 68 weeks, compared with 2.4% in the placebo group.

The majority of patients responded to treatment, with 83.5% achieving clinically meaningful weight loss, compared with 31.1% of patients receiving placebo.

More recent evidence from the STEP UP phase 3b randomised clinical trial evaluated a higher 7.2 mg maintenance dose of semaglutide in adults living with obesity.

At 72 weeks, participants receiving 7.2 mg achieved an average weight loss of ~20.7% compared with the standard 2.4 mg dose and placebo. 33.2% of participants lost ~25% of their starting body weight.

National Institute for Health and Care Excellence (NICE) has recommended Wegovy for weight management in adults living with obesity, based on the strength of the clinical trial evidence.

Can Wegovy Help with Other Conditions?

While Wegovy (semaglutide) has shown great results for weight loss, research shows it might have additional benefits.

The SELECT [1] study, conducted world-wide with over 17,000 patients, aimed to demonstrate Wegovy’s ability to reduce a patient’s chances of experiencing a repeat cardiovascular event (such as a heart attack or stroke).

The study appeared to be successful, showing a 20% risk reduction (SELECT trial – See section 5.1 – here) – so you are 20% less likely to have a heart attack/stroke if you have had one previously, independent of weight lost.

This shows that Wegovy has specific beneficial properties on the heart.

This is what sets Wegovy apart from other similar weight loss medications; it has significant evidence to back up its positive impact on reducing the risk of a secondary heart attack or stroke.

So, if you have cardiovascular disease, such as a previous heart attack or stroke, and are in two minds as to which weight loss option is for you, this may be a point of difference.

If you have any questions about our treatment options, and their benefits, please contact our clinical team or support desk.

Wegovy Side Effects

As with all medicines, some people may experience side effects from the treatment. Not everyone will get them and a majority will be mild. Only 5.3% of patients in one clinical trial stopped Wegovy due to side effects.

The most common Wegovy side effects are:

• Headache
• Vomiting
• Diarrhoea
• Constipation
• Nausea
• Abdominal pain
• Fatigue

These side effects usually improve over time as your body gets used to the medicine. Gradually increasing the dose every 4 weeks helps to reduce the risk of experiencing these side effects. If you find your side effects are severe or aren’t improving, ask your doctor or pharmacist for advice.

See section 4 of the Wegovy patient information leaflet for a complete list of possible side effects.

 

Wegovy and Pregnancy

Wegovy should not be used during pregnancy, as it may harm the foetus. Treatment should be stopped at least 2 months before a planned pregnancy. Wegovy should also not be used while breastfeeding.

 

Wegovy Alternatives

There are many alternative weight loss treatments available in the UK, including Orlistat and its branded equivalent Xenical.

Saxenda is the closest medicine to Wegovy currently licensed for weight loss in the UK. It works in the same way and is manufactured by the same company, Novo Nordisk. Saxenda is injected once daily into the abdomen, thigh or upper arm.

Mounjaro is another injectable weight loss treatment now available in the UK. It works in a similar way to Wegovy but contains a different active ingredient, tirzepatide. Tirzepatide is a dual agonist GLP-1/GIP. Mounjaro is taken once weekly and has been shown to help patients achieve significant weight loss.

Ozempic is also available to buy from some UK weight loss clinics. Ozempic also contains Semaglutide, the same active ingredient that’s in Wegovy. However, the treatment is licensed for use in diabetes. While it is legal to prescribe it for weight loss, we currently choose not to do so, due to the possible impact on diabetic patients who require this medication.

An oral version of Wegovy is currently in development and has received FDA approval in the United States. It contains the same active ingredient – semaglutide – but is taken as a once-daily tablet rather than a weekly injection.

The Wegovy pill not yet available in the UK. The MHRA is reviewing the application, with a decision expected by the seconde half of 2026. We will update this page as soon as it becomes available to prescribe through Simple Online Pharmacy.